- Email: [email protected]
Cisplatin + Vinorelbine Treatment of Recurrent or Metastatic Salivary Gland Malignancies (Rmsgm): a Final Report on 60 Cases
Annals of Oncology 25 (Supplement 4): iv340–iv356, 2014 doi:10.1093/annonc/mdu340.44
head and neck cancer 1029P
CISPLATIN + VINORELBINE TREATMENT OF RECURRENT OR METASTATIC SALIVARY GLAND MALIGNANCIES (RMSGM): A FINAL REPORT ON 60 CASES
abstracts
Aim: RMSGM are not suitable for conventional treatment. We report the clinical outcomes of 60 patients affected by RMSGM who were treated with DDP + VNB as a first- or second-line scheme.
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_4/iv353/2241743 by guest on 24 October 2019
O. Ostellino1, M. Garzaro2, F. Pedani1, M. Airoldi1, E. Bellini1, L. Raimondo2, G. Pecorari2 1 SC Oncologia 2, Città della Saluta e della Scienza, Torin, ITALY 2 Surgical Sciences Department, 1st ENT Division - University of Turin, Turin, ITALY
Methods: Sixty patients between 2001 and 2008, affected by RMSGM were enrolled in this cohort prospective study; they received the following first- or second-line CT, for a maximum of 6 cycles: DDP at 80 mg/m2 on d 1 + VNB at 25 mg/ m2 on d 1 and 8, at 3-wk intervals. Results: Seventy percent of the patients received DDP + VNB as the first-line CT and 30% of them received it as the second-line CT. After 5 cycles (median) of first-line DDP + VNB, 7% of the patients achieved a CR, 24% achieved a PR, 33% achieved an NC and 36% achieved a PD. After 4 cycles (median) of second-line CT, 0 patients achieved a CR, 5% achieved a PR, 33% achieved an NC and 62% achieved a PD. The median OS period was 10 months for those who received the first-line CT and 4 months for those who received the second-line CT. The best ORR (54%) and median survival were observed, during first line treatment, in adenocarcinomas, whereas undifferentiated tumours were unresponsive with a poor median survival (4.6 months). Conclusions: Adenocarcinomas show the best response and prognosis with DDP + VNB scheme that seems to be an effective and well-tolerated first-line CT for RMSGM, whereas it has only low palliative activity as a second-line CT. Disclosure: All authors have declared no conflicts of interest.
head and neck cancer 1029P
CISPLATIN + VINORELBINE TREATMENT OF RECURRENT OR METASTATIC SALIVARY GLAND MALIGNANCIES (RMSGM): A FINAL REPORT ON 60 CASES
abstracts
Aim: RMSGM are not suitable for conventional treatment. We report the clinical outcomes of 60 patients affected by RMSGM who were treated with DDP + VNB as a first- or second-line scheme.
© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_4/iv353/2241743 by guest on 24 October 2019
O. Ostellino1, M. Garzaro2, F. Pedani1, M. Airoldi1, E. Bellini1, L. Raimondo2, G. Pecorari2 1 SC Oncologia 2, Città della Saluta e della Scienza, Torin, ITALY 2 Surgical Sciences Department, 1st ENT Division - University of Turin, Turin, ITALY
Methods: Sixty patients between 2001 and 2008, affected by RMSGM were enrolled in this cohort prospective study; they received the following first- or second-line CT, for a maximum of 6 cycles: DDP at 80 mg/m2 on d 1 + VNB at 25 mg/ m2 on d 1 and 8, at 3-wk intervals. Results: Seventy percent of the patients received DDP + VNB as the first-line CT and 30% of them received it as the second-line CT. After 5 cycles (median) of first-line DDP + VNB, 7% of the patients achieved a CR, 24% achieved a PR, 33% achieved an NC and 36% achieved a PD. After 4 cycles (median) of second-line CT, 0 patients achieved a CR, 5% achieved a PR, 33% achieved an NC and 62% achieved a PD. The median OS period was 10 months for those who received the first-line CT and 4 months for those who received the second-line CT. The best ORR (54%) and median survival were observed, during first line treatment, in adenocarcinomas, whereas undifferentiated tumours were unresponsive with a poor median survival (4.6 months). Conclusions: Adenocarcinomas show the best response and prognosis with DDP + VNB scheme that seems to be an effective and well-tolerated first-line CT for RMSGM, whereas it has only low palliative activity as a second-line CT. Disclosure: All authors have declared no conflicts of interest.